
DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target
DENTSPLY SIRONA (XRAY) Analyst Ratings
Bulls say
Dentsply Sirona has demonstrated strong revenue growth across various segments, with orthodontics posting a double-digit percentage increase and essential dental solutions generating $372 million in sales, reflecting a 7.8% rise on a reported basis. Furthermore, Wellspect Healthcare showcased significant performance with reported revenue increases of 15.6% and 6.9% during different reporting periods, indicating robust demand for their products. Additionally, sales growth in Europe at 9.9% underscores the company's expanding market presence and resilience in a competitive landscape.
Bears say
Dentsply Sirona has revised its sales outlook downward, now anticipating a decline of 4% to 5% in constant currency, compared to a previous estimate of 2% to 4%. The company's gross margin is expected to decrease by 160 basis points in Q3 2025 relative to the same period in 2024, along with a projected drop in adjusted EBITDA margins to 17.5% for 2026, down from 18.1% in 2025. Additionally, revenues from its connected technology solutions segment have reported a decline, compounded by pressure in its orthodontics and implants segment, particularly due to challenges associated with the Byte clear aligner offering.
This aggregate rating is based on analysts' research of DENTSPLY SIRONA and is not a guaranteed prediction by Public.com or investment advice.
DENTSPLY SIRONA (XRAY) Analyst Forecast & Price Prediction
Start investing in DENTSPLY SIRONA (XRAY)
Order type
Buy in
Order amount
Est. shares
0 shares